Mostrando 121 - 137 Resultados de 137 Para Buscar '"Deauville"', tiempo de consulta: 1.40s Limitar resultados
  1. 121
    “…Lesion response was evaluated at 3 and 6 months (PET(3months) and PET(6months)) based on Deauville criteria. Anatomical changes based on ceCT at baseline and at 6 and 12 months were investigated by the sum of perpendiculars (SPD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 122
  3. 123
  4. 124
    “…PET during the interim was evaluated using Deauville 5-point scales (5-PS), ΔSUV(max) criteria, and the Peking criteria which interpreted based on the maximum standard uptake of the liver (SUV(max-liver)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  5. 125
    “…The response status on iPET was defined according to the standard five-point Deauville scores (DS) as follows: complete metabolic response (CMR, DS 1–3) and non-complete metabolic response (nCMR) (DS 4 and 5). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  6. 126
    “…In total, 119 (75%) patients reached M1 evaluation; 64 (53%, 64/119) had a complete response (CR); 91% were Deauville Score (DS) 1-3. Progression-free survival (PFS) and overall survival (OS) were significantly worse in patients with DS-5 at M1, than in patients with DS 1-3 (PFS hazard ratio [HR]=6.37, 95% confidence interval [CI]: 3.5-11.5 vs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 127
    “…%Δ changes in fasting blood sugar, (18)FDG dose, uptake time, and liver SUV mean were 3.96%, 2.83%, 2.49%, and 12.15%, respectively. Based on Deauville's scoring, cohort was divided into responders having Score 1–3 (49/97) and nonresponders having Score 4–5 (48/97). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 128
  9. 129
    “…PET/CT analysis was based on the IMPeTUs criteria, which take into consideration—among others—the metabolic state of the bone marrow based on the 5-point Deauville score (DS), the number and metabolic state of focal [(18)F]FDG-avid lesions, as well as the presence of paramedullary disease (PMD) and extramedullary disease (EMD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 130
    “…In anti-CD20 therapy, the highest pooled hazard ratios (HRs) of baseline, early, and late response monitoring parameters for progression-free survival (PFS) belong to metabolic tumor volume (MTV) (3.19 (95%CI: 2.36–4.30)), maximum standardized uptake value (SUVmax) (3.25 (95%CI: 2.08–5.08)), and Deauville score (DS) (3.73 (95%CI: 2.50–5.56)), respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 131
  12. 132
    “…METHODS: Interim PET/CT (I-PET) and end of treatment PET/CT (EoT-PET) scans of 81 MYC + and 129 MYC- DLBCL patients from 2 HOVON trials were reviewed using the Deauville 5-point scale (DS). DS1-3 was regarded as negative and DS4-5 as positive. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 133
    “…Patients with negative PET/CT (Deauville scores 1–2) received 2 additional cycles of rituximab monotherapy, unless they had any risk factors (primary mediastinal large B-cell lymphoma, extranodal primary or bulky disease). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 134
    “…Three patients (50.0%) relapsed for ≥ 2 times and 3 patients (50.0%) had primary refractory diseases. All had a Deauville score of 4 or 5, and 5 patients (83.3%) had a stable or progressive disease (SD/PD) at enrollment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 135
    “…The chi-squared test showed that TMTV0, STMTV0, Dmax, SUVmax1, TMTV1, TTLG1, %ΔSUVmax, Deauville score, IPI, Ann Arbor stage, and LDH were associated with patient prognosis (P < 0.05). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 136
    “…PET scans were performed at baseline, after two cycles of chemotherapy, and end of treatment (EOT). The Deauville five-point scale (5-PS) was used in the initial staging and assessment of treatment response. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  17. 137
    por Koh, Dow-Mu, Kaste, Sue Creviston, Vinnicombe, Sarah J., Morana, Giovanni, Rossi, Andrea, Herold, Christian J., McLoud, Theresa C., Frey, Kirk A., Gebauer, Bernhard, Roebuck, Derek, Fütterer, Jurgen J., Towbin, Alexander J., Huisman, Thierry A. G., Smets, Anne M. J. B., Morana, Giovanni, Lee, Jeong Min, Chandarana, Hersh, Mayerhoefer, Marius E., Raderer, Markus, Haug, Alexander, Eiber, Matthias, Gebauer, Bernhard, Rockall, Andrea, Sohaib, Aslam, Warbey, Victoria S, Vargas, Hebert Alberto, Koh, Dow-Mu, Heiken, Jay P., Francis, Isaac R., Al-Hawary, Mahmoud M., Kaza, Ravi K., Morana, Giovanni, D’Onofrio, Mirko, Thoeny, Harriet C., King, Ann D., Morana, Giovanni, Piccardo, Arnoldo, Garrè, Maria Luisa, Rossi, Andrea, Vargas, Hebert Alberto, McLoud, Theresa C., Reed, Nick, Rodriguez-Galindo, Carlos, Chandarana, Hersh, Vargas, Hebert Alberto, Francis, Isaac R., Wasnik, Ashish P., Diederich, Stefan, Fütterer, Jurgen J., Oyen, Wim J. G., Chaw, Cheng Lee, van As, Nicholas, Vieira, Igor, De Keyzer, Frederik, Dresen, Elleke, Han, Sileny, Vergote, Ignace, Moerman, Philippe, Amant, Frederic, Koole, Michel, Vandecaveye, Vincent, Dresen, R., De Vuysere, S., De Keyzer, F., Van Cutsem, E., D’Hoore, A., Wolthuis, A., Vandecaveye, V., Pricolo, P., Alessi, S., Summers, P., Tagliabue, E., Petralia, G., Pfannenberg, C., Gückel, B., Schüle, S. C., Müller, A. C., Kaufmann, S., Schwenzer, N., Reimold, M., la Fougere, C., Nikolaou, K., Martus, P., Cook, G. J., Azad, G. K., Taylor, B. P., Siddique, M., John, J., Mansi, J., Harries, M., Goh, V., Seth, S., Burgul, R., Seth, A., Waugh, S., Gowdh, N. Muhammad, Purdie, C., Evans, A., Crowe, E., Thompson, A., Vinnicombe, S., Arfeen, F., Campion, T., Goldstraw, E., D’Onofrio, M., Ciaravino, V., Crosara, S., De Robertis, R., Mucelli, R. Pozzi, Uhrig, M., Simons, D., Schlemmer, H., Downey, Kate, Murdoch, S., Al-adhami, A. S., Viswanathan, S., Smith, S., Jennings, P., Bowers, D., Soomal, R., Smith, S., Jennings, P., Bowers, D., Soomal, R., Mutala, T. M., Odhiambo, A. O., Harish, N., Pricolo, P., Alessi, S., Summers, P., Tagliabue, E., Petralia, G., Hall, M., Sproule, M., Sheridan, S., Thein, K. Y., Tan, C. H., Thian, Y. L., Ho, C. M., De Luca, S., Carrera, C., Blanchet, V., Alarcón, L., Eyheremnedy, E., Choudhury, B. K., Bujarbarua, K., Barman, G., Cook, G. J., Lovat, E., Siddique, M., Goh, V., Ferner, R., Warbey, V. S., Potti, L., Kaye, B., Beattie, A., Dutton, K., Seth, A. A., Constantinidis, F., Dobson, H., Seth, A. A., Constantinidis, F., Dobson, H., Bradley, R., Bozas, G., Avery, G., Stephens, A., Maraveyas, A., Bhuva, S., Johnson, C. A., Subesinghe, M., Taylor, N., Quint, L. E., Reddy, R. M., Kalemkerian, G. P., Zapico, G. González, Jauregui, E. Gainza, Francisco, R. Álvarez, Alonso, S. Ibáñez, Bahillo, I. Tavera, Álvarez, L. Múgica, Francies, O., Wheeler, R., Childs, L., Adams, A., Sahdev, A., De Luca, S. E., Vañek, M. E. Casalini, Pascuzzi, M. D., Gillanders, T., Ramos, P. M., Eyheremendy, E. P., Stove, C., Digby, M., Nazar, M., Wirtz, M., Pascuzzi, M. D., Troncoso, F., Saguier, F., Eyheremendy, E. P., Quint, D. J., Dang, L., Carlson, M., Leber, S., Silverstein, F., Rueben, R., Viswanathan, S., Nazir, B., Teo, T. H., Khoo, J. B., Sharma, K., Gupta, N., Mathew, B., Jeyakumar, T., Harkins, K., Sharma, K., Mathew, B., Gupta, N., Jeyakumar, T., Joshua, S., Christodoulou, D., Gourtsoyianni, S., Jacques, A., Griffin, N., Goh, V., Johnson, C. A., Lee, J., Goodfellow, J. A., Al-adhami, A. S., Viswanathan, S., Bradley, R., Bradley, R., Yong, A., Jenkins, S., Joseph, G., Bhuva, S., Partington, K., Johnson, C. A., Bhuva, S., Subesinghe, M., Taylor, N., Carrera, C., Zanfardini, A., De Luca, S., Alarcón, L., Blanchet, V., Eyheremendy, E. P., Cavanagh, K., Lau, E.
    Publicado 2016
    “…Mayerhoefer, Markus Raderer, Alexander Haug O18 Managing high-risk and advanced prostate cancer Matthias Eiber O19 Immunotherapy: imaging challenges Bernhard Gebauer O20 RECIST and RECIST 1.1 Andrea Rockall O21 Challenges of RECIST in oncology imaging basics for the trainee and novice Aslam Sohaib O22 Lymphoma: PET for interim and end of treatment response assessment: a users’ guide to the Deauville Score Victoria S Warbey O23 Available resources Hebert Alberto Vargas O24 ICIS e-portal and the online learning community Dow-Mu Koh O25 Benign lesions that mimic pancreatic cancer Jay P Heiken O26 Staging and reporting pancreatic malignancies Isaac R Francis, Mahmoud, M Al-Hawary, Ravi K Kaza O27 Intraductal papillary mucinous neoplasm Giovanni Morana O28 Cystic pancreatic tumours Mirko D’Onofrio O29 Diffusion-weighted imaging of head and neck tumours Harriet C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS